Taysha Gene Therapies, Inc.
TSHA · Biological Products, (No Diagnostic Substances) · 287.4M shares · +88%/yr ↑ shares · EDGAR filings ↗
Reference price $4.46 · est. market cap ~$1.3B — last insider sale, 2026-04-10 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — gene-therapy clinical, heavy burn ($94M), very well-funded.
Strengths
- Liquidity — current ratio 12.2 (87th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Net lossNet loss (net margin -1115.3%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Cash burnNegative free cash flow (-93.8M)
- Strong balance sheetStrong balance sheet — $320M cash & investments, ~14 quarters of runway
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 5 notable fund(s): GOLDMAN SACHS GROUP INC, FMR LLC, STATE STREET CORP +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 9 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$4M, last 6mo) Form 4 ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-1130.6%
Net margin
-1115.3%
Return on equity
-44.1%
Return on assets
-31.7%
ROIC
-29.4%
Revenue growth (QoQ)
-100.0%
Debt / equity
0.2×
Current ratio
12.2×
Free cash flow
-$94M
Tangible book value
$247M
Cash & investments
$320M
Cash runway
14q
Stock comp / revenue
136.1%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | Sepp-Lorenzino Laura | Grant | 21K | — |
| 2026-06-01 | Stalfort John A III | Grant | 21K | — |
| 2026-06-01 | Donenberg Phillip B. | Grant | 21K | — |
| 2026-06-01 | Long Alison S | Grant | 21K | — |
| 2026-04-10 | Nagendran Sukumar | Option exercise | 19K | $1.71 |
| 2026-04-10 | Nagendran Sukumar | Sell | 200K | $4.46 |
| 2026-02-04 | Alam Kamran | Sell | 1.7K | $4.52 |
| 2026-01-26 | Alam Kamran | Sell | 24K | $4.61 |
| 2026-01-26 | Nagendran Sukumar | Sell | 27K | $4.61 |
| 2026-01-26 | Nolan Sean P. | Sell | 41K | $4.61 |
| 2026-01-23 | Alam Kamran | Sell | 79K | $4.75 |
| 2026-01-23 | Nagendran Sukumar | Sell | 89K | $4.75 |
| 2026-01-23 | Nolan Sean P. | Sell | 137K | $4.75 |
| 2026-01-12 | Nolan Sean P. | Grant | 1.0M | — |
| 2026-01-12 | Alam Kamran | Grant | 359K | — |
| 2026-01-12 | Nagendran Sukumar | Option exercise | 111K | $0.70 |
| 2026-01-12 | Nagendran Sukumar | Option exercise | 89K | $1.71 |
| 2026-01-12 | Nagendran Sukumar | Sell | 200K | $4.71 |
| 2026-01-12 | Nagendran Sukumar | Grant | 427K | — |
| 2025-12-01 | Nagendran Sukumar | Option exercise | 260K | $1.71 |
| 2025-12-01 | Nagendran Sukumar | Sell | 260K | $4.51 |
| 2025-11-28 | Nagendran Sukumar | Sell | 110K | $4.75 |
| 2025-11-28 | Nagendran Sukumar | Option exercise | 70K | $0.70 |
| 2025-11-28 | Nagendran Sukumar | Option exercise | 40K | $1.71 |
| 2025-09-10 | Nagendran Sukumar | Option exercise | 41K | $0.70 |
| 2025-09-10 | Nagendran Sukumar | Sell | 200K | $3.23 |
| 2025-08-21 | Nagendran Sukumar | Sell | 57K | $2.85 |
| 2025-08-21 | Alam Kamran | Sell | 54K | $2.85 |
| 2025-06-02 | Stalfort John A III | Grant | 57K | — |
| 2025-06-02 | Donenberg Phillip B. | Grant | 57K | — |
| 2025-06-02 | Long Alison S | Grant | 57K | — |
| 2025-06-02 | Sepp-Lorenzino Laura | Grant | 57K | — |
| 2025-05-30 | Manning Paul B | Buy | 750K | $2.75 |
| 2025-03-11 | Alam Kamran | Tax withheld | 30K | $1.69 |
| 2025-01-02 | Nolan Sean P. | Grant | 892K | — |
| 2025-01-02 | Nagendran Sukumar | Grant | 324K | — |
| 2025-01-02 | Alam Kamran | Grant | 431K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07480564 ↗ | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome Rett Syndrome | PHASE3 | Recruiting | 2031-06-01 |
| NCT05606614 ↗ | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) Rett Syndrome | PHASE3 | Recruiting | 2031-06-01 |
| NCT06152237 ↗ | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) Rett Syndrome | PHASE1/PHASE2 | Active Not Recruiting | 2028-11-02 |
| NCT05277363 ↗ | A Study of the Natural Course of SURF1 Deficiency Leigh Syndrome | — | Withdrawn | 2022-05-04 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-25 | Material agreementOtherExhibits | filing ↗ |
| 2026-06-22 | Reg FDOtherExhibits | filing ↗ |
| 2026-06-02 | Shareholder vote | filing ↗ |
| 2026-05-06 | ResultsExhibits | filing ↗ |
| 2026-03-19 | ResultsExhibits | filing ↗ |
| 2025-11-04 | Material agreementResultsExhibits | filing ↗ |
| 2025-10-16 | OtherExhibits | filing ↗ |
| 2025-10-09 | OtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-25 | 2026-06-24 | 0001193125-26-282855 ↗ |
| 8-K | 2026-06-22 | 2026-06-22 | 0001193125-26-276738 ↗ |
| 8-K | 2026-06-02 | 2026-06-01 | 0001193125-26-253478 ↗ |
| 10-Q | 2026-05-06 | 2026-03-31 | 0001193125-26-207666 ↗ |
| 8-K | 2026-05-06 | 2026-05-06 | 0001193125-26-207633 ↗ |
| 8-K | 2026-03-19 | 2026-03-19 | 0001193125-26-115177 ↗ |
| 10-K | 2026-03-19 | 2025-12-31 | 0001193125-26-115202 ↗ |
| 8-K | 2025-11-04 | 2025-11-04 | 0001193125-25-263543 ↗ |
| 10-Q | 2025-11-04 | 2025-09-30 | 0001193125-25-263506 ↗ |
| 8-K | 2025-10-16 | 2025-10-16 | 0001193125-25-241415 ↗ |
| 8-K | 2025-10-09 | 2025-10-09 | 0001193125-25-235212 ↗ |
| 8-K | 2025-10-02 | 2025-10-02 | 0001193125-25-227505 ↗ |